NEW YORK, Dec. 15 (GenomeWeb News) - Cenix BioScience said today that it has signed a deal to use its genome-wide siRNA library to help Bayer screen all known human druggable genes in an effort to identify and validate new drug targets.
Cenix said that, using cell-based assays developed in partnership with Bayer researchers, it expects to screen more than 6,000 genes in less than nine months.
Under the terms of the deal, Cenix will receive upfront fees and research funding, and is eligible for milestone payments. Bayer will have an option to obtain all rights to new intellectual property generated by the effort.
Additional terms were not disclosed.